“Sarcopenia Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcopenia Market.

The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sarcopenia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Sarcopenia treatment therapies with a considerable amount of success over the years.

• Sarcopenia companies working in the treatment market are TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others, are developing therapies for the Sarcopenia treatment

• Emerging Sarcopenia therapies in the different phases of clinical trials are- MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others are expected to have a significant impact on the Sarcopenia market in the coming years.

• In September 2025, Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company focused on treatments for neuromuscular and fibrotic diseases, announced positive Phase 1 trial results for MF-300, a novel therapy under development for sarcopenia. The trial met its primary safety endpoint, with all tested doses of MF-300 generally well tolerated and no participant discontinuations. MF-300 showed dose-dependent pharmacodynamic (PD) responses that were evident early and maintained over time, while the placebo group showed no significant changes, confirming target engagement and biological activity. Pharmacokinetic (PK) analysis revealed dose-related increases in exposure, with a half-life supporting convenient once-daily oral dosing.

• In July 2025, Epirium Bio Inc., a clinical-stage biopharmaceutical company focused on neuromuscular and fibrotic diseases, announced the completion of dosing in its Phase 1 trial of MF-300. This randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD/MAD) study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of MF-300 in healthy adults. MF-300, an investigational first-in-class oral inhibitor of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme, is being developed to treat sarcopenia, or age-related muscle weakness. Preliminary findings showed all adverse events were mild to moderate, with no severe or serious cases, no early discontinuations, and no stopping criteria met.

• In April 2025, TNF Pharmaceuticals, Inc. announced that Mitchell Glass, M.D., President and Chief Medical Officer of TNF, delivered a platform presentation on the abstract titled “Isomyosamine for the Treatment of Sarcopenia in Older Adults” at the British Geriatrics Society (BGS) Spring Meeting 2025, which took place from April 9–11 in Belfast, Ireland, and online.

Sarcopenia Overview

Muscle mass, strength, and performance are severely hampered with age in sarcopenia, a musculoskeletal condition. Elderly, sedentary individuals as well as people with concomitant conditions that impact the musculoskeletal system or limit physical exercise are most frequently affected by sarcopenia.

Get a Free Sample PDF Report to know more about Sarcopenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight

Emerging Sarcopenia Drugs Under Different Phases of Clinical Development Include:

• MYMD-1/Isomyosamine: TNF Pharmaceuticals

• LPCN 1148: Lipocine

• Sarconeos (BIO101): Biophytis

• Froniglutide (PF-1801): ImmunoForge

• RJx-01: Rejuvenate Biomed

• KER-065: Keros Therapeutics

• BPM 31510 (ubidecarenone): BPGbio

• OC514: Oncocross

• MT29: Mirscience Therapeutics

• TRN-005: Turn Biotechnologies

• NMDP-05: NMD PHARMA

• PF1807: ImmunoForge

• DW1030: Dong Wha PHARM

Sarcopenia Route of Administration

Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Sarcopenia Molecule Type

Sarcopenia Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Sarcopenia Pipeline Therapeutics Assessment

• Sarcopenia Assessment by Product Type

• Sarcopenia By Stage and Product Type

• Sarcopenia Assessment by Route of Administration

• Sarcopenia By Stage and Route of Administration

• Sarcopenia Assessment by Molecule Type

• Sarcopenia by Stage and Molecule Type

DelveInsight’s Sarcopenia Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Sarcopenia product details are provided in the report. Download the Sarcopenia pipeline report to learn more about the emerging Sarcopenia therapies

Some of the key companies in the Sarcopenia Therapeutics Market include:

Key companies developing therapies for Sarcopenia are – Abbott Nutrition, GSK PLC, Nestle Health Science, Sanofi SA, Bayer AG, Novartis AG, Metagenics LLC, Wellona Pharma, Intas Pharmaceuticals Ltd, Perrigo Company PLC, Dr. Jockers Store, and others.

Sarcopenia Pipeline Analysis:

The Sarcopenia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.

• Sarcopenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sarcopenia drugs and therapies

Sarcopenia Pipeline Market Drivers

• Increase in Prevalence of Sarcopenia, increase in Research and development activities are some of the important factors that are fueling the Sarcopenia Market.

Sarcopenia Pipeline Market Barriers

• However, complications of Sarcopenia treatment, lack of awareness about the disease and other factors are creating obstacles in the Sarcopenia Market growth.

Scope of Sarcopenia Pipeline Drug Insight

• Coverage: Global

• Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others

• Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others

• Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies

• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers

Request for Sample PDF Report for Sarcopenia Pipeline Assessment and clinical trials

Table of Contents

1. Sarcopenia Report Introduction

2. Sarcopenia Executive Summary

3. Sarcopenia Overview

4. Sarcopenia- Analytical Perspective In-depth Commercial Assessment

5. Sarcopenia Pipeline Therapeutics

6. Sarcopenia Late Stage Products (Phase II/III)

7. Sarcopenia Mid Stage Products (Phase II)

8. Sarcopenia Early Stage Products (Phase I)

9. Sarcopenia Preclinical Stage Products

10. Sarcopenia Therapeutics Assessment

11. Sarcopenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sarcopenia Key Companies

14. Sarcopenia Key Products

15. Sarcopenia Unmet Needs

16 . Sarcopenia Market Drivers and Barriers

17. Sarcopenia Future Perspectives and Conclusion

18. Sarcopenia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/